Efficacy of Ciltacabtagene Autoleucel in Chinese Patients With Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
J. Clin. Oncol 2022 Oct 21;[EPub Ahead of Print], JQ Mi, W Zhao, H Jing, W Fu, J Hu, L Chen, Y Zhang, D Yao, D Chen, JM Schecter, F Yang, X Tian, H Sun, SH Zhuang, J Ren, X Fan, J Jin, T Niu, SJ ChenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.